当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Abstract：

:There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable endogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type and null states, we show that p53 is spontaneously active in all tested tissues of mdm2-deficient mice, triggering fatal pathologies that include ablation of classically radiosensitive tissues. In apoptosis-resistant tissues, spontaneous unbuffered p53 activity triggers profound inhibition of cell proliferation. Such acute spontaneous p53 activity occurs in the absence of any detectable p53 posttranslational modification, DNA damage, or p19ARF signaling and triggers rapid p53 degradation.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Ringshausen I,O'Shea CC,Finch AJ,Swigart LB,Evan GI

doi

10.1016/j.ccr.2006.10.010

subject

Has Abstract

pub_date

2006-12-01 00:00:00

pages

501-14

issue

6

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(06)00316-3

journal_volume

10

pub_type

杂志文章

相关文献

CANCER CELL文献大全
  • Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

    abstract：:Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion of pre-malignant cells via transcriptional silencing of proliferation-related genes due to decoration of their promoters with repressive trimethylated histone H3 lysine 9 (H3K9) marks. We show here that structurally distinct H3K9-active d...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.01.002

    authors： Yu Y,Schleich K,Yue B,Ji S,Lohneis P,Kemper K,Silvis MR,Qutob N,van Rooijen E,Werner-Klein M,Li L,Dhawan D,Meierjohann S,Reimann M,Elkahloun A,Treitschke S,Dörken B,Speck C,Mallette FA,Zon LI,Holmen SL,Peeper DS

    更新日期：2018-02-12 00:00:00

  • MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.

    abstract：:MYC is an oncogenic driver that regulates transcriptional activation and repression. Surprisingly, mechanisms by which MYC promotes malignant transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC ch...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.09.001

    authors： Tu WB,Shiah YJ,Lourenco C,Mullen PJ,Dingar D,Redel C,Tamachi A,Ba-Alawi W,Aman A,Al-Awar R,Cescon DW,Haibe-Kains B,Arrowsmith CH,Raught B,Boutros PC,Penn LZ

    更新日期：2018-10-08 00:00:00

  • Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.

    abstract：:Antiangiogenic tumor therapy has failed in the adjuvant setting. Here we show that inhibition of the Tie2 ligand angiopoietin-2 (Ang2) effectively blocks metastatic growth in preclinical mouse models of postsurgical adjuvant therapy. Ang2 antibody treatment combines well with low-dose metronomic chemotherapy (LDMC) in...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.005

    authors： Srivastava K,Hu J,Korn C,Savant S,Teichert M,Kapel SS,Jugold M,Besemfelder E,Thomas M,Pasparakis M,Augustin HG

    更新日期：2014-12-08 00:00:00

  • AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

    abstract：:Homeotic (HOX) genes are dysregulated in multiple malignancies, including several AML subtypes. We demonstrate that H3K79 dimethylation (H3K79me2) is converted to monomethylation (H3K79me1) at HOX loci as hematopoietic cells mature, thus coinciding with a decrease in HOX gene expression. We show that H3K79 methyltrans...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.10.009

    authors： Deshpande AJ,Deshpande A,Sinha AU,Chen L,Chang J,Cihan A,Fazio M,Chen CW,Zhu N,Koche R,Dzhekieva L,Ibáñez G,Dias S,Banka D,Krivtsov A,Luo M,Roeder RG,Bradner JE,Bernt KM,Armstrong SA

    更新日期：2014-12-08 00:00:00

  • A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

    abstract：:Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mT...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.01.014

    authors： Fan Q,Aksoy O,Wong RA,Ilkhanizadeh S,Novotny CJ,Gustafson WC,Truong AY,Cayanan G,Simonds EF,Haas-Kogan D,Phillips JJ,Nicolaides T,Okaniwa M,Shokat KM,Weiss WA

    更新日期：2017-03-13 00:00:00

  • Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage.

    abstract：:E proteins and their functional antagonists, the ID proteins, have significant roles in normal hematopoiesis. In this issue of Cancer Cell, Ghisi et al. show that high ID2 levels antagonize self-renewal and promote differentiation of leukemic stem cells in the MLL-translocated molecular subtype of acute myeloid leukem...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.06.006

    authors： Deb G,Somervaille TCP

    更新日期：2016-07-11 00:00:00

  • Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia.

    abstract：:A subset of B cell acute lymphoblastic leukemia (B-ALL) patients will relapse and succumb to therapy-resistant disease. The bone marrow microenvironment may support B-ALL progression and treatment evasion. Utilizing single-cell approaches, we demonstrate B-ALL bone marrow immune microenvironment remodeling upon diseas...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.04.015

    authors： Witkowski MT,Dolgalev I,Evensen NA,Ma C,Chambers T,Roberts KG,Sreeram S,Dai Y,Tikhonova AN,Lasry A,Qu C,Pei D,Cheng C,Robbins GA,Pierro J,Selvaraj S,Mezzano V,Daves M,Lupo PJ,Scheurer ME,Loomis CA,Mullighan CG,

    更新日期：2020-06-08 00:00:00

  • Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

    abstract：:Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by expression of the p210-BCR-ABL fusion protein. We demonstrate in a murine model of p210-BCR-ABL-induced MPD that gene targeting of Rac1 and Rac2 significantly delays or abrogates disease development. Attenuation of the disease...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2007.10.015

    authors： Thomas EK,Cancelas JA,Chae HD,Cox AD,Keller PJ,Perrotti D,Neviani P,Druker BJ,Setchell KD,Zheng Y,Harris CE,Williams DA

    更新日期：2007-11-01 00:00:00

  • Targeting the Residual Leukemia Cells after Chemotherapy.

    abstract：:One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML r...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2018.08.012

    authors： Vu LP,Kharas MG

    更新日期：2018-09-10 00:00:00

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    abstract：:Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development have not b...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.06.001

    authors： Moran-Crusio K,Reavie L,Shih A,Abdel-Wahab O,Ndiaye-Lobry D,Lobry C,Figueroa ME,Vasanthakumar A,Patel J,Zhao X,Perna F,Pandey S,Madzo J,Song C,Dai Q,He C,Ibrahim S,Beran M,Zavadil J,Nimer SD,Melnick A,Godley LA

    更新日期：2011-07-12 00:00:00

  • Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

    abstract：:Undifferentiated sarcomas (USARCs) of adults are diverse, rare, and aggressive soft tissue cancers. Recent sequencing efforts have confirmed that USARCs exhibit one of the highest burdens of structural aberrations across human cancer. Here, we sought to unravel the molecular basis of the structural complexity in USARC...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.02.002

    authors： Steele CD,Tarabichi M,Oukrif D,Webster AP,Ye H,Fittall M,Lombard P,Martincorena I,Tarpey PS,Collord G,Haase K,Strauss SJ,Berisha F,Vaikkinen H,Dhami P,Jansen M,Behjati S,Amary MF,Tirabosco R,Feber A,Campbell PJ,

    更新日期：2019-03-18 00:00:00

  • RalGDS is required for tumor formation in a model of skin carcinogenesis.

    abstract：:To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor i...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.01.029

    authors： González-García A,Pritchard CA,Paterson HF,Mavria G,Stamp G,Marshall CJ

    更新日期：2005-03-01 00:00:00

  • New Views into the Genetic Landscape of Metastatic Breast Cancer.

    abstract：:Whether metastasis-specific genetic alterations exist remains controversial. The study by Yates et al. in this issue of Cancer Cell provides evidence that metastases emerge late during primary breast cancer progression and that additional driver mutations are often acquired, posing both challenges and opportunities fo...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.07.011

    authors： Zhao X,Powers S

    更新日期：2017-08-14 00:00:00

  • PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia.

    abstract：:PML/RARalpha is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeutically. Using a genome-wide approach, we identified in vivo PML/RARalpha binding sites in a PML/RARalpha-inducible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of thes...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.12.045

    authors： Wang K,Wang P,Shi J,Zhu X,He M,Jia X,Yang X,Qiu F,Jin W,Qian M,Fang H,Mi J,Yang X,Xiao H,Minden M,Du Y,Chen Z,Zhang J

    更新日期：2010-02-17 00:00:00

  • Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

    abstract：:Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.02.002

    authors： Atwood SX,Sarin KY,Whitson RJ,Li JR,Kim G,Rezaee M,Ally MS,Kim J,Yao C,Chang AL,Oro AE,Tang JY

    更新日期：2015-03-09 00:00:00

  • GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.

    abstract：:Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarker...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.06.007

    authors： Karantanos T,Thompson TC

    更新日期：2013-07-08 00:00:00

  • Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

    abstract：:In mice, Lkb1 deletion and activation of Kras(G12D) results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lk...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.04.026

    authors： Carretero J,Shimamura T,Rikova K,Jackson AL,Wilkerson MD,Borgman CL,Buttarazzi MS,Sanofsky BA,McNamara KL,Brandstetter KA,Walton ZE,Gu TL,Silva JC,Crosby K,Shapiro GI,Maira SM,Ji H,Castrillon DH,Kim CF,García-Echeve

    更新日期：2010-06-15 00:00:00

  • Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

    abstract：:We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics s...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.09.001

    authors： Robichaux JP,Elamin YY,Vijayan RSK,Nilsson MB,Hu L,He J,Zhang F,Pisegna M,Poteete A,Sun H,Li S,Chen T,Han H,Negrao MV,Ahnert JR,Diao L,Wang J,Le X,Meric-Bernstam F,Routbort M,Roeck B,Yang Z,Raymond VM,Lanman

    更新日期：2019-10-14 00:00:00

  • A molecular view of anti-ErbB monoclonal antibody therapy.

    abstract：:Abnormal activation of the epidermal growth factor receptor (EGFR) and its homolog HER2 (Neu/ErbB2) has been associated with many human cancers, and monoclonal antibodies targeting EGFR and HER2 are effective anticancer therapies. Structural studies of these receptors and antibodies have revealed much about how they f...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2008.03.010

    authors： Leahy DJ

    更新日期：2008-04-01 00:00:00

  • High-throughput Phenotyping of Lung Cancer Somatic Mutations.

    abstract：:Recent genome sequencing efforts have identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood. Here we characterize 194 somatic mutations identified in primary lung adenocarcinomas. We present an expression-based variant-impact phenotyping (eVIP) method ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.06.022

    authors： Berger AH,Brooks AN,Wu X,Shrestha Y,Chouinard C,Piccioni F,Bagul M,Kamburov A,Imielinski M,Hogstrom L,Zhu C,Yang X,Pantel S,Sakai R,Watson J,Kaplan N,Campbell JD,Singh S,Root DE,Narayan R,Natoli T,Lahr DL,Tiro

    更新日期：2016-08-08 00:00:00

  • Successful targeting of ErbB2 receptors-is PTEN the key?

    abstract：:Women with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy treatment is ineffective. The ErbB2-targeted antibody trastuzumab improves survival when given with chemotherapy to patients with ErbB2-overexpressing metastatic disease, but treatment is not curative, and primary resistance is...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2004.08.001

    authors： Crowder RJ,Lombardi DP,Ellis MJ

    更新日期：2004-08-01 00:00:00

  • M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.

    abstract：:In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction nee...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2019.06.004

    authors： Srour N,Mersaoui SY,Richard S

    更新日期：2019-07-08 00:00:00

  • Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

    abstract：:Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.014

    authors： Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

    更新日期：2013-01-14 00:00:00

  • Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

    abstract：:Somatic genetic alterations of IKZF1, which encodes the lymphoid transcription factor IKAROS, are common in high-risk B-progenitor acute lymphoblastic leukemia (ALL) and are associated with poor prognosis. Such alterations result in the acquisition of stem cell-like features, overexpression of adhesion molecules causi...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.03.021

    authors： Churchman ML,Qian M,Te Kronnie G,Zhang R,Yang W,Zhang H,Lana T,Tedrick P,Baskin R,Verbist K,Peters JL,Devidas M,Larsen E,Moore IM,Gu Z,Qu C,Yoshihara H,Porter SN,Pruett-Miller SM,Wu G,Raetz E,Martin PL,Bowman

    更新日期：2018-05-14 00:00:00

  • Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

    abstract：:Activating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitoc...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.02.003

    authors： Haq R,Shoag J,Andreu-Perez P,Yokoyama S,Edelman H,Rowe GC,Frederick DT,Hurley AD,Nellore A,Kung AL,Wargo JA,Song JS,Fisher DE,Arany Z,Widlund HR

    更新日期：2013-03-18 00:00:00

  • Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer.

    abstract：:The nervous system is emerging as a regulator of malignancy. In this issue of Cancer Cell, Hayakawa et al. demonstrate a feedforward signaling loop in which tumor-derived nerve growth factor promotes enteric tumor innervation, and recruited nerves drive cancer growth through acetylcholine-regulated Wnt signaling and s...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.12.008

    authors： Monje M

    更新日期：2017-01-09 00:00:00

  • Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

    abstract：:Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(02)00043-0

    authors： Kondo K,Klco J,Nakamura E,Lechpammer M,Kaelin WG Jr

    更新日期：2002-04-01 00:00:00

  • Stressing Out about Cancer Immunotherapy.

    abstract：:Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2019.10.013

    authors： He XY,Ng D,Van Aelst L,Egeblad M

    更新日期：2019-11-11 00:00:00

  • The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

    abstract：:Tumors constitute highly suppressive microenvironments in which infiltrating T cells are "exhausted" by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor and other CD8(+) T cell-dependent chronic immune responses. TIGIT is highly expressed on human an...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.10.018

    authors： Johnston RJ,Comps-Agrar L,Hackney J,Yu X,Huseni M,Yang Y,Park S,Javinal V,Chiu H,Irving B,Eaton DL,Grogan JL

    更新日期：2014-12-08 00:00:00

  • Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

    abstract：:To identify oncogenic pathways in T cell acute lymphoblastic leukemia (T-ALL), we combined expression profiling of 117 pediatric patient samples and detailed molecular-cytogenetic analyses including the Chromosome Conformation Capture on Chip (4C) method. Two T-ALL subtypes were identified that lacked rearrangements o...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.02.008

    authors： Homminga I,Pieters R,Langerak AW,de Rooi JJ,Stubbs A,Verstegen M,Vuerhard M,Buijs-Gladdines J,Kooi C,Klous P,van Vlierberghe P,Ferrando AA,Cayuela JM,Verhaaf B,Beverloo HB,Horstmann M,de Haas V,Wiekmeijer AS,Pike-Over

    更新日期：2011-04-12 00:00:00